COG announced the early study results of ANBL0032. They have determined that the immunotherapy (experimental) arm of the study – a combination of ch14.18 antibody, cytokines (IL2 and GMCSF) and Accutane more effectively reduces the risk that neuroblastoma will grow back than treatment with Accutane alone. Furthermore they have determined that the immunotherapy, as specifically delivered on COG ANBL0032, increases the chance of survival after completion of therapy including stem cell transplantation when compared to treatment with cisRA alone. According to the statement they now expect that this immunotherapy may eventually become a standard part of high-risk neuroblastoma treatment after stem cell transplant. More info at:
http://www.curesearch.org/uploadedFiles/Statement%20from%20COG%20regarding%20ANBL0032%20results%2003%2019%2009.pdf
Posted on 03-19-2009
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment